Skip to main content

Chronic Rhinosinusitis With Nasal Polyposis

3
Pipeline Programs
3
Companies
4
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
2
0
1
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
2100%
+ 3 programs with unclassified modality

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Keymed Biosciences
Keymed BiosciencesChina - Chengdu
3 programs
2
1
CM310Phase 31 trial
CM512Phase 21 trial
CM512Phase 21 trial
Active Trials
NCT06930612Completed120Est. Jul 2026
NCT07519577Not Yet Recruiting120Est. May 2028
NCT05436275Completed180Est. Jun 2024
Sanofi
SanofiPARIS, France
1 program
DupilumabN/AMonoclonal Antibody1 trial
Active Trials
NCT06393946Active Not Recruiting150Est. Jul 2026
Regeneron
RegeneronTARRYTOWN, NY
1 program
DupilumabN/AMonoclonal Antibody

Trial Timeline

Clinical trial activity over time

2022
2023
2024
2025
2026
2027
2028
Keymed BiosciencesCM310
Keymed BiosciencesCM512
Keymed BiosciencesCM512
SanofiDupilumab

Clinical Trials (4)

Total enrollment: 570 patients across 4 trials

NCT05436275Keymed BiosciencesCM310

A Study of CM310 in Patients With Chronic Rhinosinusitis With Nasal Polyposis （CROWNS-2）

Start: Aug 2022Est. completion: Jun 2024180 patients
Phase 3Completed
NCT07519577Keymed BiosciencesCM512

A Study of CM512 in Patients With Chronic Rhinosinusitis With Nasal Polyposis （NEZHA-2）

Start: May 2026Est. completion: May 2028120 patients
Phase 2Not Yet Recruiting
NCT06930612Keymed BiosciencesCM512

A Study of CM512 in Patients With Chronic Rhinosinusitis With Nasal Polyposis （NEZHA-1）

Start: May 2025Est. completion: Jul 2026120 patients
Phase 2Completed
NCT06393946SanofiDupilumab

Study in Adults With Severe Chronic Rhinosinusitis With Nasal Polyposis Treated With Dupilumab in France

Start: Oct 2023Est. completion: Jul 2026150 patients
N/AActive Not Recruiting

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.